<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:department>Pharmaceutics</gtr:department><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/57E997FA-7341-4710-AEA2-5F84D8309962"><gtr:id>57E997FA-7341-4710-AEA2-5F84D8309962</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/377FA252-3443-4D9A-A9F0-8B52AB44A52F"><gtr:id>377FA252-3443-4D9A-A9F0-8B52AB44A52F</gtr:id><gtr:firstName>J. Paul</gtr:firstName><gtr:surname>Luzio</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C5408F79-E297-4CFB-9A94-977B26D51DB3"><gtr:id>C5408F79-E297-4CFB-9A94-977B26D51DB3</gtr:id><gtr:firstName>Brendan</gtr:firstName><gtr:surname>Wren</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400268"><gtr:id>FAE2DAC8-E7A2-4F82-A1B6-F2BA538A4E56</gtr:id><gtr:title>Treatment of Systemic Infection by Modification of the Bacterial Phenotype</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400268</gtr:grantReference><gtr:abstractText>Meningitis and sepsis remain devastating diseases, particularly in the young. If patients survive, there are usually serious consequences that include mental retardation, seizures, cerebral palsy and hearing loss. Antibiotic therapy may not always be effective because the infection progresses very rapidly and antibiotic resistant bacteria are now more commonly found. There is widespread recognition that new approaches to the treatment of the disease are urgently needed. These serious infections in the newborn infant and in older children are caused by a relatively small number of bacterial types and they are almost all protected from the effects of the patient?s immune system by a coat, or capsule, comprising linked sugar molecules. There is ample evidence that the capsule is essential for the survival of the bacteria within the tissues of the patient, as without it they are no longer able to protect themselves from immune attack. We are looking for ways to rapidly remove this protective layer as a novel way of treating the infection ? our approach, which we call phenotypic modification, does not rely on directly killing the bacteria in the way that most antibiotics do, but aims to convert them to a ?less fit? form that cannot survive in the body. We have found an enzyme, derived from a bacterial virus or ?bacteriophage?, which quickly and selectively strips the capsule from the bacterial surface and sensitises the pathogenic organisms to the body?s defences. We have used the enzyme to treat experimental infections in newborn rats and we find that injection of very small amounts of material can very effectively cure the animals of what is invariably a fatal infection. This is the first demonstration that we know of which shows that ?phenotypic modification? can work in whole animals. We now which to achieve a greater understanding of the nature of the infection in the animal model by studying the distribution of the pathogen in animal tissues and organs and we would also like to establish that the positive therapeutic outcome that we observe is really due to removal of the protective capsule at the site of infection. Finally, we propose to use ?microarray technology? to establish whether key rat gene products are involved in the determination of the therapeutic outcome.</gtr:abstractText><gtr:technicalSummary>Capsulate bacteria cause a range of severe systemic infections and there is a large body of evidence linking their invasive potential to expression of capsular polysaccharides on the bacterial surface. This relationship is particularly strong with Gram-negative bacteria causing sepsis and meningitis, and relatively few capsular serotypes are responsible for most of these infections. Escherichia coli K1 strains are a common cause of sepsis and meningitis in the newborn, and produce capsules composed of alpha-2,8-linked polysialic acid (PSA) that significantly enhances virulence. The difficulty of treating these infections is compounded by the steady increase in antibiotic resistance associated with these pathogens. We are developing an approach to the treatment of these infections based on modulation of capsule expression at the bacterial surface; removal or inhibition of biosynthesis of PSA may disarm these organisms and allow the patients? host defences to counter the infection. We have established that this principle (abrogation of infection by modification of the bacterial phenotype) is sound by treating E. coli K1-infected neonatal rats with endosialidase E (endoE), which specifically hydrolyses PSA. Intraperitoneal administration of small quantities of the protein (0.25mcg), given as a single dose early in the course of the infection, abolishes bacteraemia and prevents death. 

We now wish to establish parameters for enzyme-mediated cure of systemic infection in the neonatal rat model and define the key events that determine the outcome of the infection and its resolution by endoE. We will produce sufficient quantities of highly pure recombinant endoE to allow structural elucidation of the enzyme. Structural data will enable us to improve the pharmacokinetic properties by removing non-essential domains from the protein and to design non-catalytic enzyme mutants to establish beyond doubt that in vivo catalysis of PSA is essential for endoE-mediated abrogation of infection. The whole body distribution of E. coli K1 in neonatal rats will be determined at appropriate time points after intestinal colonisation by orally administered bacteria using microbiological, histological and immunohistochemical techniques.In addition, we will evaluate the effect of enzyme treatment on this bioburden. Finally, we will investigate the effects of K1 infection, and its treatment with endoE, on the major organs of the neonatal rat using histopathological techniques and determine the effects of infection and treatment on gene expression in selected organs using DNA microarrays. The proposal represents a thorough programme of basic research to develop a novel therapy that may have wider therapeutic application</gtr:technicalSummary><gtr:fund><gtr:end>2008-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>239121</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Gothenburg</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Mucin Biology Group</gtr:department><gtr:description>K1 histochemistry</gtr:description><gtr:id>4C4CC91F-487E-4B1C-9053-E7387413E1A9</gtr:id><gtr:impact>Manuscript based on mucin layer integrity in preparation; graduated PhD student from my laboratory has joined the mucin biology group at the University of Gothenburg led by Gunnar Hansson.</gtr:impact><gtr:partnerContribution>Determination of mucin barrier integrity and site of K1 translocation from gut to blood</gtr:partnerContribution><gtr:piContribution>Providing tissue samples for determination of temporal and physiological parameters associated with E. coli K1 gastrointestinal colonization, including Tff2 composition of mucin.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Gothenburg</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Mucin Biology Group</gtr:department><gtr:description>K1 histochemistry</gtr:description><gtr:id>E648EE9F-74F5-4B3E-BC6E-81A0D4E3FE2D</gtr:id><gtr:impact>Manuscript based on mucin layer integrity in preparation; graduated PhD student from my laboratory has joined the mucin biology group at the University of Gothenburg led by Gunnar Hansson.</gtr:impact><gtr:partnerContribution>Determination of mucin barrier integrity and site of K1 translocation from gut to blood</gtr:partnerContribution><gtr:piContribution>Providing tissue samples for determination of temporal and physiological parameters associated with E. coli K1 gastrointestinal colonization, including Tff2 composition of mucin.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turku</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>K1-GFP fusion protein</gtr:description><gtr:id>1844E98C-96A8-4717-92F6-A293F0A4A3FE</gtr:id><gtr:impact>We provide compelling evidence that the neonatal rat pup model, unlike almost all of alternatives, possesses key features of the infection in the human neonate: non-invasive establishment of infection following colonisation of the intestinal tract; a strong age dependency; temporal development along the gut-blood-brain transit; colonisation and penetration of the meninges after invasion of the cerebral spinal compartment. A192PP efficiently produced a systemic lethal infection in almost all pups, with considerable organ involvement. Nevertheless, small single doses of endoE resolved infection in the majority of animals and prevented death. As far as can be ascertained, resolution of the infection was due to in situ removal of the capsule from bacteria in the blood compartment.</gtr:impact><gtr:partnerContribution>Produced by recombination technology a GFP fusion protein as a key reagent for histological localisation obacteria in rat tissues</gtr:partnerContribution><gtr:piContribution>We undertook histochemical characterisation of tisssues using this reagent</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>radio interview - Broadcasting House</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10242129-51F1-4AA7-9230-AC03A98ED98B</gtr:id><gtr:impact>I was interviewed about my research by this Radio 4 programme with respect to control of notifiable diseases and the work from thisd MRC grant was part of the feature

I was invited to participate in a NewsNight BBC2 programme on a related topic the following year</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovation Award</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AC534DDB-103A-4E86-A89A-E665C9D4383A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D64B956-A768-42BF-93AA-27F4380F5856"><gtr:id>0D64B956-A768-42BF-93AA-27F4380F5856</gtr:id><gtr:title>Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/38564134ae3f1c4901942aa2a91b752f"><gtr:id>38564134ae3f1c4901942aa2a91b752f</gtr:id><gtr:otherNames>Zelmer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7298D6B9-7ABA-4CCC-BBA5-2F9DCCDFEE88"><gtr:id>7298D6B9-7ABA-4CCC-BBA5-2F9DCCDFEE88</gtr:id><gtr:title>Antibiotic Resistance: Causes and Risk Factors</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6eaf2ef81cd221b160402e18b393905"><gtr:id>f6eaf2ef81cd221b160402e18b393905</gtr:id><gtr:otherNames>Taylor Peter W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:isbn>978-1607416234</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E3F69AF-A505-4E3C-A774-E9BD036571E4"><gtr:id>0E3F69AF-A505-4E3C-A774-E9BD036571E4</gtr:id><gtr:title>Differential expression of the polysialyl capsule during blood-to-brain transit of neuropathogenic Escherichia coli K1.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/38564134ae3f1c4901942aa2a91b752f"><gtr:id>38564134ae3f1c4901942aa2a91b752f</gtr:id><gtr:otherNames>Zelmer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55E5C5A0-67E3-4858-B414-0A195B5640C2"><gtr:id>55E5C5A0-67E3-4858-B414-0A195B5640C2</gtr:id><gtr:title>Non-invasive model of neuropathogenic Escherichia coli infection in the neonatal rat.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fd4727b922b647204502f8094c4ce363"><gtr:id>fd4727b922b647204502f8094c4ce363</gtr:id><gtr:otherNames>Dalgakiran F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE8B8C1C-A81F-4918-9C56-617CA6CC701A"><gtr:id>EE8B8C1C-A81F-4918-9C56-617CA6CC701A</gtr:id><gtr:title>Altered innate defenses in the neonatal gastrointestinal tract in response to colonization by neuropathogenic Escherichia coli.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/534a6fb4bc1bd526a33ff136f415ce83"><gtr:id>534a6fb4bc1bd526a33ff136f415ce83</gtr:id><gtr:otherNames>Birchenough GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400268</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>